Ken Heebner's Firm Exits Zebra Technologies, Phillips 66

MoneyWise
Joe Biden says this is when the next stimulus checks will go out
The legislation is advancing quickly. Here's how much you're likely to get, and when.
2h ago
MoneyWise
To get the next stimulus check, you may want to hustle with your taxes
The bill that passed the Senate makes payments harder to get. Your tax return might help.
4h ago
Barrons.com
Cathie Wood’s New Tesla Target Price Is Coming Soon. Here’s Where It Might Land.
ARK Investment founder Cathie Wood says her new Tesla price target is coming soon. What will it be? Barron's hazards a back-of-the-envelope guess.
5h ago
Investor's Business Daily
Getting A Third Covid-19 Stimulus Check Just Got Tougher — But You Might Still Influence How Big Yours Is
Congress is nearing passage of the third economic stimulus check it will send out to you and other taxpayers as part of its Covid-19 relief bill.
18h ago
MoneyWise
Joe Biden's stimulus check changes: Do you still qualify for $1,400?
To win Senate passage, Biden agreed to make millions ineligible for the third checks.
4h ago
TipRanks
JPMorgan Bets on These 3 Stocks; Sees Over 50% Upside Potential
It’s time to check in with the macro picture, to get an idea of just where markets are headed in the coming months. That’s what a JPMorgan global research team, headed up by Joyce Chang, has been doing. The JPM team starts by noting the sell-off in US Treasury bonds last week, pushing up yields as investors acted in response to inflationary fears. However, the rise in bond yields steadied on Friday, and Chang’s team does not believe that inflation is the great bugaboo it’s made out to be; her team sees a combination of economic growth and fiscal stimulus creating a virtuous circle of consumer spending fueling more growth. They write, “Our global economics team is now forecasting US nominal GDP to average roughly 7% growth over this year and next as targeted measures have been successful in addressing COVID-19 and economic activity is not being jeopardized. Global growth will exceed 5%...” What this means, in JPM’s view, is that the coming year should be good for stocks. Interest rates are likely to remain low, in the firm’s estimation, while inflation should moderate as the economy returns to normal. JPM’s stock analysts have been following the strategy team, and seeking out the stocks they see as winners over the next 12 months. Three of their recent picks make for an interesting lot, with Strong Buy ratings from the analyst community and over 50% upside potential. We’ve used the TipRanks database to pull the details on them. Let’s take a look. On24 (ONTF) The first JPM pick were looking at here is On24, the online streaming service that offers third parties access for scaled and personalized networked events. In other words, On24 makes its streaming service available for other companies to use in setting up interactive features, including webinars, virtual events, and multi-media experiences. The San Francisco-based company boasts a base of more than 1900 corporate users. On24’s customers engage online with more than 4 million professionals every month, for more than 42 million hours every year. As can be imagined, On24 saw a surge of customer interest and business in the past year, as virtual offices and telecommuting situations expanded – and the company has now used that as a base for going public. On24 held its IPO last month, and entered the NYSE on February 3. The opening was a success; 8.56 million shares were put on the market at $77 each, well above the $50 initial pricing. However, shares have taken a beating since, and have dropped by 36%. Nevertheless, JPM’s Sterling Auty thinks the company is well-placed to capitalize on current trends. “The COVID-19 pandemic, we believe, has changed the face of B2B marketing and sales forever. It has forced companies to move most of their sales lead generation into the digital world where On24 is typically viewed as the best webinar/webcast provider.” the 5-star analyst wrote. “Even post-pandemic we expect the marketing motion to be hybrid with digital and in-person being equally important. That should drive further adoption of On24-like solutions, and we expect On24 to capture a material share of that opportunity.” In line with these upbeat comments, Auty initiated coverage of the stock with an Overweight (i.e., Buy) rating, and his $85 price target suggests it has room for 73% upside over the next 12 months. (To watch Auty’s track record, click here.) Sometimes, a company is just so solid and successful that Wall Street’s analysts line up right behind it – and that is the case here. The Strong Buy analyst consensus rating is unanimous, based on 8 Buy-side reviews published since the stock went public just over a month ago. The shares are currently trading for $49.25 and their $74 average price target implies an upside of 50% from that level. (See On24’s stock analysis at TipRanks.) Plug Power, Inc. (PLUG) And moving over to the reusable energy sector, we’ll take a look at a JPM ‘green power’ pick. Plug Power designs and manufactures hydrogen power cells, a technology with a great deal of potential as a possible replacement for traditional batteries. Hydrogen power cells have potential applications in the automotive sector, as power packs for alt-fuel cars, but also in just about any application that involves the storage of energy – home heating, portable electronics, and backup power systems, to name just a few. Over the past year, PLUG shares have seen a tremendous surge, rising over 800%. The stock got an additional boost after Joe Biden’s presidential election win – and his platform promises to encourage ‘Green Energy.” But the stock has pulled back sharply recently, as many over-extended growth names have. Poor 4Q20 results also help explain the recent selloff. Plug reported a deep loss of $1.12 per share, far worse than the 8-cent loss expected, or the 7-cent loss reported in the year-ago quarter. In fact, PLUG has never actually reported positive earnings. This company is supported by the quality of its technology and that tech’s potential for adoption as industry moves toward renewable energy sources – but we aren’t there yet, despite strides in that direction. The share price retreat makes PLUG an attractive proposition, according to JPM analyst Paul Coster. “In the context of the firm's many long-term growth opportunities, we believe the stock is attractively priced at present, ahead of potential positive catalysts, which include additional ‘pedestal’ customer wins, partnerships and JVs that enable the company to enter new geographies and end-market applications quickly and with modest capital commitment,” the analyst said. “At present, PLUG is a story stock, appealing to thematic investors as well as generalists seeking exposure to Renewable Energy growth, and Hydrogen in particular.” Coster’s optimistic comments come with an upgrade to PLUG’s rating - from a Neutral (i.e., Hold) to Overweight (Buy) - and a $65 price target that indicates a possible 55% upside. (To watch Coster’s track record, click here.) Plug Power has plenty of support amongst Coster’s colleagues, too. 13 recent analyst reviews break down to 11 Buys and 1 Hold and Sell, each, all aggregating to a Strong Buy consensus rating. PLUG shares sell for $39.3 and have an average price target of $62.85, which suggests a 60% one-year upside potential. (See Plug’s stock analysis at TipRanks.) Orchard Therapeutics, PLC (ORTX) The last JPM stock pick we’ll look at is Orchard Therapeutics, a biopharma research company focused on the development of gene therapies for the treatment of rare diseases. The company’s goal is to create curative treatments from the genetic modification of blood stem cells – treatments which can reverse the causative factors of the target disease with a single dosing. The company’s pipeline features two drug candidates that have received approval in the EU. The first, OTL-200, is a treatment for Metachromatic leukodystrophy (MLD), a serious metabolic disease leading to losses of sensory, motor, and cognitive functioning. Strimvelis, the second approved drug, is a gammaretroviral vector-based gene therapy, and the first such ex vivo autologous gene therapy to receive approve by the European Medicines Agency. It is a treatment for adenosine deaminase deficiency (ADA-SCID), when the patient has no available related stem cell donor. In addition to these two EU-approved drugs, Orchard has ten other drug candidates in various stages of the pipeline process, from pre-clinical research to early-phase trials. Anupam Rama, another of JPM’s 5-star analysts, took a deep dive into Orchard and was impressed with what he saw. In his coverage of the stock, he notes several key points: “Maturing data across various indications in rare genetic diseases continues to de-risk the broader ex vivo autologous gene therapy platform from both an efficacy / safety perspective… Key opportunities in MLD (including OTL-200 and other drug candidates) have sales potential each in the ~$200-400M range… Importantly, the overall benefit/risk profile of Orchard’s approach is viewed favorably in the eyes of physicians. At current levels, we believe ORTX shares under-reflect the risk-adjusted potential of the pipeline...” The high sales potential here leads Rama to rate the stock as Outperform (Buy) and to set a $15 price target, implying a robust 122% upside potential in the next 12 months. (To watch Rama’s track record, click here.) Wall Street generally is in clear agreement with JPM on this one, too. ORTX shares have 6 Buy reviews, for a unanimous Strong Buy analyst consensus rating, and the $15.17 average price target suggests a 124% upside from the current $6.76 trading price. (See Orchard’s stock analysis at TipRanks.) Disclaimer: The opinions expressed in this article are solely those of the featured analysts. The content is intended to be used for informational purposes only. It is very important to do your own analysis before making any investment.
7h ago
MoneyWise
How stimulus checks can give you a $14,000 windfall this year
Some households are collecting a big pile of federal money in 2021.
2d ago
InvestorPlace
Churchill Capital IV Will Likely Create Shareholder Value
Following weeks of speculation, special purpose acquisition company Churchill Capital IV (NYSE:CCIV) announced it will merge with California-based Lucid Motors. Investors have been bullish on CCIV stock since the start of the year after rumors began flying about reverse merger. Source: ggTravelDiary / Shutterstock.com The shares jumped from $10 to a record high of $64.86 on Feb. 18. Now, they are near $24. It is important to remember that Lucid Motors is still a pre-revenue auto group. Lucid CEO Peter Rawlinson recently said that orders for its first vehicle, the Lucid Air, have been “overwhelming.”InvestorPlace - Stock Market News, Stock Advice & Trading Tips The first model is likely to be shipped in the summer of 2020. Its first-stage factory in Arizona is ready to produce 34,000 vehicles a year. Management hopes in a couple of years the number could reach 400,000 per year. 9 Cheap Stocks That Look Like a Bargain Now investors wonder what might be next for CCIV stock. Given the recent decline in price, the risk/return profile of the shares are better for buy-and-hold investors. If you are not a shareholder, you might regard upcoming dips in the share price as an opportunity to invest in this new company. What To Expect From the Merger Lucid Motors is vying to become leader in the luxury electric vehicle (EV) market. Over the past year, TSLA (NASDAQ:TSLA) stock is up about 300%. In general, EV market has been very hot. As a result, investors in CVIS stock have wondering if their new company could be a potential Tesla rival. The merger values Lucid Motors at $24 billion. It will also mean Lucid will have about $4.4 billion in cash, which in part can be used to expand manufacturing, Rawlinson said: Financing from the transaction will also be used to support expansion of our manufacturing facility in Arizona, which is the first greenfield purpose-built EV manufacturing facility in North America, and is already operational for pre-production builds of the Lucid Air, … [with its] projected range of over 500 miles on a single charge – ahead of all competitors on the market today. Often, the success of a black check company depends on the management team. Churchill Capital CEO Michael Klein is well-known Wall Street veteran. He has already completed several mergers. For instance two years ago, Churchill announced a merger with Clarivate Analytics, a leading global provider of comprehensive intellectual property and scientific information, analytical tools and services. In July 2020, Churchill Capital Corp III struck an $11 billion deal with healthcare company MultiPlan (NYSE:MPLN), in one of the largest deals for a SPAC. So, while CCIV stock has no operating business, the management team is experienced in the SPAC space to potentially make the next deal a success. Furthermore, Saudi Arabia’s sovereign wealth fund is a strategic investor in Lucid. Therefore, the company has access to significant amounts of capital. Despite the frothy valuation of the company, investors are excited about the prospects. Bottom Line on CCIV Stock It is too soon to know how the share price of CCIV stock will move in the coming quarters. Lucid is still a startup automotive company with exciting prospects. A successful merger could be the start of a very appealing investment, one that many will keep their eyes on. But large amounts of capital and time are required before significant revenue will be made. Given the interest of the Street in EVs as well as the background of the two companies, I believe the merger will create shareholder value in the long run. However, potential investors should still carefully study the risk/return profile of investing in the company at this point. On the date of publication, Tezcan Gecgil did not have (either directly or indirectly) any positions in the securities mentioned in this article. Tezcan Gecgil has worked in investment management for over two decades in the U.S. and U.K. In addition to formal higher education in the field, she has also completed all 3 levels of the Chartered Market Technician (CMT) examination. Her passion is for options trading based on technical analysis of fundamentally strong companies. She especially enjoys setting up weekly covered calls for income generation. More From InvestorPlace Why Everyone Is Investing in 5G All WRONG It doesn’t matter if you have $500 in savings or $5 million. Do this now. Top Stock Picker Reveals His Next Potential 500% Winner Stock Prodigy Who Found NIO at $2… Says Buy THIS Now The post Churchill Capital IV Will Likely Create Shareholder Value appeared first on InvestorPlace.
2d ago
InvestorPlace
Carnival Is Climbing Too High Too Fast
Shares of Carnival Cruise Lines (NYSE:CCL) have climbed approximately 20% in the last month. That puts CCL stock within hailing distance of its pre-pandemic price. I understand that the market is forward thinking, but this seems to be an example of irrational exuberance. Source: Kokoulina / Shutterstock.com As of now, over 82 million Americans have received a Covid-19 vaccine. This is evidence, not just hope, but empirical evidence that the pandemic is much better. But still, CCL seems to be a stock that’s moved too high, too fast. In this article, I’ll explain why.InvestorPlace - Stock Market News, Stock Advice & Trading Tips Ships Are Still In Port My colleague Josh Enomoto pointed out that airline passenger volume was up to about 38% of pre-pandemic levels from Feb. 1 through Feb. 19. Undoubtedly, those numbers will look even better as they are compared to pandemic numbers in the coming months. 9 Cheap Stocks That Look Like a Bargain However, airlines were operating, albeit in dribs and drabs, throughout the pandemic. Carnival is not going to be sailing for quite some time. In January, the company stated that the Carnival Magic, Carnival Paradise and Carnival Valor will not resume operations until November 2021. Overall, the cruise line will not be resuming operation until June of this year. And that isn’t all. Here are just three headlines on Cardinal’s investor relations website: Their Princess Cruises line extended its pause of cruises on Roundtrip Southampton sailings through Sept. 25. Princess Cruises also extended its pause of cruises to select Alaska, Canada & New England and Pacific Coastal sailings. The company Seabourn line announces cancellation of every 2021 Alaska/British Columbia voyages. This simply means it’s going to be quite some time before the cruise line sees smooth sailing from a revenue perspective. Waiting On Revenue In 2020, Carnival brought in about 5.6 billion in revenue. That was a year-over-year decline of more than 70%. However, that included a first quarter in which the company was operating under pre-pandemic conditions. When you look at the following four quarters, including the first quarter of 2021 that the company reported in January, the revenue picture is even worse. Not surprisingly Carnival announced it was raising $1 billion from a public offering. Investors took a brief pause, but then CCL stock began trading at nearly a 12-month high. And it’s also important to note that CCL stock was flat to slightly negative throughout much of 2019. And keep in mind that in 2019, the company had slightly more revenue than it delivered in 2018. It would be one thing if Carnival was a pre-revenue company. But they’re not. Yet investors are buying CCL stock as if it was. That’s not a formula for success, when it’s likely that the company won’t start delivering meaningful revenue before 2022. Wait For a Better Price For CCL Stock I’m not intending to bash Carnival. The Covid-19 pandemic hit cruise lines particularly hard. As I noted above, airlines at least had a trickle of revenue. The same was true of hotels. But cruise lines were literally banned from sailing. I believe the company is being transparent with investors. It’s not their fault, and to their benefit, that investors are getting excited about CCL stock. But that doesn’t make it a good investment at this time. The stock price is approximating where the company was, revenue-wise, prior to the pandemic. However, the cruise line won’t be sailing for months. On the date of publication Chris Markoch did not have (either directly or indirectly) any positions in the securities mentioned in this article. Chris Markoch is a freelance financial copywriter who has been covering the market for seven years. He has been writing for Investor Place since 2019. More From InvestorPlace Why Everyone Is Investing in 5G All WRONG It doesn’t matter if you have $500 in savings or $5 million. Do this now. Top Stock Picker Reveals His Next Potential 500% Winner Stock Prodigy Who Found NIO at $2… Says Buy THIS Now The post Carnival Is Climbing Too High Too Fast appeared first on InvestorPlace.
2d ago
Yahoo Finance
Roblox goes public, inflation data: What to know in the week ahead
This week, investors will be eyeing new inflation data, which will offer a look at whether prices have already begun to creep up as some have feared ahead of a major economic reopening. A highly anticipated direct listing for the vide0 game company Roblox is also on deck.
5h ago
Benzinga
Why Cathie Wood Is Bullish On DraftKings
Ark Funds CEO and Founder Cathie Wood joined Benzinga’s “Raz Report” this week and discussed the history of Ark Funds. Wood also shared some of the reasons why Ark Funds owns several positions, including in DraftKings Inc (NASDAQ: DKNG). Wood on DraftKings: Wood told Benzinga that DraftKings is becoming accepted as a platform for sports betting as the public grows more comfortable with the activity. “We do think sports betting is losing its taint,” Wood said. The fund manager sees more states turning toward legalizing sports betting, especially as many face huge deficits, Wood said. Wood used New Jersey as an example of the success states can have. The state is a mature market and DraftKings’ revenue was up 100% in the state. “New Jersey was very telling to us," she said. Ark Funds: DraftKings was added to two different Ark Funds beginning in February. Ark Next Generation Internet ETF (NYSE: ARKW) owns around 1.4 milion shares of DraftKings worth $88.1 million. Ark Fintech Innovation ETF (NYSE: ARKF) owns around 546,000 shares of DraftKings worth $33.8 million. DraftKings represents around 1.2% and 0.8% of ARKW and ARKF, respectively. Price Action: Shares of DraftKings finished the week down 6.24% at $59.52. Related Link: DraftKings And Dish Network Partner On Sports Betting, TV Integration See more from BenzingaClick here for options trades from BenzingaFuboTV Shares Pop On Caesars Partnership, Access To Additional States For Sports BettingHorizon Acquisition Corp SPAC Jumps 20% On Potential Sportradar Merger© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
1d ago
Bloomberg
Biggest Players in the Short-Selling Game Are Getting a Pass
(Bloomberg) -- It’s in the air again, on Reddit, in Congress, in the C-suite: Hedge funds that get rich off short-selling are the enemy. The odd thing is, the biggest players in the game are getting a pass.Those would be the asset managers, pension plans and sovereign wealth funds that provide the vast majority of securities used to take bearish positions. Without the likes of BlackRock Inc. and State Street Corp., the California Public Employees’ Retirement System and the Kuwait Investment Authority filling such an elemental role, investors such as Gabe Plotkin, whose Melvin Capital Management became a piñata for day traders in the GameStop Corp. saga, wouldn’t have shares to sell short.“Anytime we short a stock, we locate a borrow,” Plotkin said Feb. 18 at the House Financial Services Committee hearing on the GameStop short squeeze.There’s plenty to choose from. As of mid-2020, some $24 trillion of stocks and bonds were available for such borrowing, with $1.2 trillion in shares -- equal to a third of all hedge-fund assets -- actually out on loan, according to the International Securities Lending Association.It’s a situation that on the surface defies logic. Given the popular belief that short sellers create unjustified losses in some stocks, why would shareholders want to supply the ammunition for attacks against their investments? The explanation is fairly straight forward: By loaning out securities for a small fee plus interest, they can generate extra income that boosts returns. That’s key in an industry where fund managers are paid to beat benchmarks and especially valuable in a world of low yields.The trade-off is simple: For investors with large, diversified portfolios, a single stock plummeting under the weight of a short-selling campaign has little impact over the long run. And in the nearer term, the greater the number of aggregate bets against a stock -- the so-called short interest -- the higher the fee a lender can charge.In the case of GameStop, short interest was unusually high and shares on loan were generating an annualized return of 25% to 30%, Ken Griffin testified at the Feb. 18 hearing. Griffin operates a market maker, Citadel Securities, as well as Citadel, one of the world’s largest hedge funds.“Securities lending is a way for long holders to generate additional alpha,” said Nancy Allen of DataLend, which compiles data on securities financing. “Originally, it was a way to cover costs, but over the last 10 to 15 years it’s become an investment function.”Not everyone is comfortable with the inherent conflict. In December 2019, Japan’s $1.6 trillion Government Pension Investment Fund stopped lending its international stock holdings to short sellers, calling the practice inconsistent with its responsibilities as a fiduciary. At the time, the decision cost GPIF about $100 million a year in lost revenue.The U.S. Securities and Exchange Commission has regulated short-selling since the 1930s and polices the market for abuses such as naked shorting, which involves taking a short position without borrowing shares. Proponents of legal shorting argue that its use enhances liquidity, improves pricing and serves a critical role as a bulwark against fraud and hype.Chief executives, whose pay packages often depend on share performance, routinely decry short sellers as vultures. More recently, shorting has come under fire in the emotionally charged banter on Reddit’s WallStreetBets forum. Some speculators ran up the prices of GameStop, AMC Entertainment Holdings Inc. and other meme stocks in January to punish the hedge funds that bet against them, and they delighted when the rampant buying led to bruising losses at Melvin, Maplelane Capital and Citron Research.Many of the key actors in the GameStop frenzy testified at the Feb. 18 hearing. Plotkin was grilled by committee members over Melvin’s short position. Citadel’s Griffin and others faced broader questions about short-selling. Yet no one asked about the supply of borrowed shares and there were no witnesses called from the securities-lending industry.There’s a symbiotic relationship between hedge funds and the prime-brokerage units of Wall Street firms, much of it built on securities lending. Prime brokers act as intermediaries, sourcing stocks and bonds for borrowers who want to short them and facilitate the trades. According to DataLend, securities lending generated $2.9 billion of broker-to-broker revenue in 2020, almost the same as in 2019.Demand for short positions was already expected to drop as stock prices surged to all-time highs. Now, with the threat of retribution from the Reddit crowd, it may weaken even further. Griffin said he has “no doubt” there’ll be less short-selling as a consequence of the GameStop squeeze.“I think the whole industry will have to adapt,” Plotkin said at the hearing. “I don’t think investors like myself want to be susceptible to these types of dynamics.”This could not only threaten the dealers who broker stock lending but also the holders who supply the securities and share in the revenue. They reaped $7.7 billion globally in 2020, down from a record of almost $10 billion in 2018, according to DataLend. Lending fees increased by 4.2% on a year-over-year basis in February after the GameStop onslaught, DataLend says.While securities lending accounted for $652 million, or just 4%, of BlackRock’s revenue in the fourth quarter of 2020, there’s little cost involved and the risks are low because borrowers have to put up collateral that equals or exceeds the value of the loan. At both BlackRock and State Street Corp., the second-largest custody bank, the value of securities on loan as of Dec. 31 jumped at least 20% from a year earlier, to $352 billion and $441 billion, respectively.“Every little bit counts with indexes,” said John Rekenthaler, vice president of research at Morningstar. “You’re scraping nickels off the street, but there’s a whole lot of nickels.”Others could take a hit, too. Just as Robinhood Markets is able to offer zero-commission trades by selling its order flow to Citadel and other market makers, asset managers typically pass on some of their securities-lending revenue as a type of client rebate.“It’s very important to remember that institutional investors earn substantial returns from participating in the securities-lending market,” Citadel’s Griffin said at the GameStop hearing. “That accrues to the benefit of pension plans, of ETFs, of other pools of institutional lending that participate in the securities lending market.”(Adds data on lending fees after the short-interest chart.)For more articles like this, please visit us at bloomberg.comSubscribe now to stay ahead with the most trusted business news source.©2021 Bloomberg L.P.
22h ago
Bloomberg
Elon Musk Loses $27 Billion as Historic Wealth Gains Unravel
(Bloomberg) -- Elon Musk set records last year for one of the fastest streaks of wealth accumulation in history. The reversal is underway, and it’s steep.The Tesla Inc. chief executive officer lost $27 billion since Monday as shares of the automaker tumbled in the selloff of tech stocks. His $156.9 billion net worth still places him No. 2 on the Bloomberg Billionaires Index, but he’s now almost $20 billion behind Jeff Bezos, who he topped just last week as world’s richest person.Musk’s tumble only underscores the hard-to-fathom velocity of his ascent. Tesla shares soared 743% in 2020, boosting the value of his stake and unlocking billions of dollars in options through his historic “moonshot” compensation package.His gains accelerated into the new year. In January, he unseated Bezos as the world’s richest person. Musk’s fortune peaked later that month at $210 billion, according to the index, a ranking of the world’s 500 wealthiest people.Consistent quarterly profits, the election of President Joe Biden with his embrace of clean technologies and enthusiasm from retail investors fueled the company’s rise, but for some, its swelling valuation was emblematic of an unsustainable frothiness in tech. The Nasdaq 100 Index fell for the third straight week on Friday, its longest streak of declines since September.Bitcoin InvestmentMusk’s fortune hasn’t been solely subject to the forces buffeting the tech industry. His net worth has risen and slumped recently in tandem with the price of Bitcoin. Tesla disclosed last month it had added $1.5 billion of the cryptocurrency to its balance sheet. Musk’s fortune took a $15 billion hit two weeks later after he mused on twitter that the prices of Bitcoin and other cryptocurrencies “do seem high.”Extreme volatility has roiled many of the world’s biggest fortunes this year. Asia’s once-richest person, Chinese bottled-water tycoon Zhong Shanshan, relinquished the title to Indian billionaire Mukesh Ambani last month after losing more than $22 billion in a matter of days.Read more: Ambani Again Richest Asian as China’s Zhong Down $22 BillionQuicken Loans Inc. Chairman Dan Gilbert’s net worth surged by $25 billion on Monday after his mortgage lender Rocket Cos. was said to be the next target of Reddit day traders. His fortune has since fallen by almost $24 billion. Alphabet Inc. co-founders Sergey Brin and Larry Page are among the biggest gainers on the index this year. They’ve each added more than $13 billion to their fortunes since Jan. 1.For more articles like this, please visit us at bloomberg.comSubscribe now to stay ahead with the most trusted business news source.©2021 Bloomberg L.P.
2d ago
Benzinga
Chamath Palihapitiya Shares Lessons Learned After Tough Week For SPACs
The last week has been a tough one for investors in many growth stocks. SPACs is one segment that was hit particularly hard. Lessons Learned From Palihapitiya: SPAC King Chamath Palihapitiya shared on Twitter Inc (NYSE: TWTR) how much he lost in the week and his thoughts on the SPAC market. “It’s been a super tough week for me and I’m sure a super tough week for some of you as well. Here is how I’m doing after Friday and what I’ve learned...” Palihapitiya tweeted. The investor broke down his lessons learned during the week as follows: “The first thing I tried to do yesterday was take a step back and try to see the bigger picture,” he said. Palihapitiya went on to say that March 2020 could be a guide as markets were down 20% then. Is this current market environment the same or different? Palihapitiya asks. He said he looked at his relative performance vs the S&P500, which breaks down as 3.6% compared to 2.3%, or 56% above the benchmark. He said he's not a "huge fan" of these numbers. “I re-questioned my goals and concluded my strategic view is still right: that inequality and climate change investments are a once in a lifetime opportunity to make hundreds of billions of dollars AND do the right thing," he said. “I freed up some capital by selling some shares in $SPCE so I can keep investing at scale without impacting my pace and strategic view.” Palihapitiya added that he hated selling the shares but had to do it after his balance sheet shrank by nearly $2 billion during the week. Palihapitiya also said he has not sold any shares of any other SPAC he’s launched. He went on to say that investing is hard, he is not perfect, and he is trying to learn just like his audience and followers on Twitter. “Be resilient and keep fighting,” he said. Markets are volatile and unforgiving, Palihapitiya added. Companies that do valuable things tend to see their value reflected in gains. “Find a way to make sure you are comfortable with what you own and if not, don’t be afraid to make changes. Prices are temporary but your peace of mind should not be,” he said. Palihapitiya ended his tweet with the Persian adage: “This too shall pass.” Related Link: 5 Things You Might Not Know About Chamath Palihapitiya Sale of Virgin Galactic Stock: The tweet from Palihapitiya came after he was in the news Friday for selling his personal stake in Virgin Galactic Holdings (NYSE: SPCE). Palihapitiya sold 6.2 million shares for around $211 million, according to Business Insider. It follows a similar sale in December. Palihapitiya still owns 15.8 million shares in Virgin Galactic through Social Capital Hedosophia, the company that Palihapitiya and partner Ian Osborne used to take the space tourism company public via SPAC. “I sold 6 million shares for $200 million, which I am planning to redirect into a large investment I am making towards fighting climate change,” Palihapitiya told Business Insider in an emailed statement. The investment will be made public in the next few months. It’s been a super tough week for me and I’m sure a super tough week for some of you as well. Here is how I’m doing after Friday and what I’ve learned... pic.twitter.com/fX5YHdqBv6 — Chamath Palihapitiya (@chamath) March 6, 2021 Disclosure: Author is long shares of SPCE. See more from BenzingaClick here for options trades from Benzinga3 Former SPACs Report Earnings: What Fisker, Velodyne Lidar, Virgin Galactic Investors Should Know© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
22h ago
Yahoo Finance
Suze Orman: Something's ‘radically wrong’ if you’re getting a tax refund
Personal finance guru Suze Orman said the receipt of a tax refund indicates "something's radically wrong," since the money returned to filers could otherwise have accrued value over the period it stood in the government's possession.
1d ago
Bloomberg
Bond Traders Go All-In on U.S. Treasury Market’s Big Short Bet
(Bloomberg) -- It’s not just in meme stocks that the fate of short sellers is a key theme. Short bets are increasingly in vogue in the $21 trillion Treasuries market, with crucial implications across asset classes.The benchmark 10-year yield reached 1.62% Friday -- the highest since February 2020 -- before dip buying from foreign investors emerged. Stronger-than-expected job creation and Federal Reserve Chair Jerome Powell’s seeming lack of concern, for now, with leaping long-term borrowing costs have emboldened traders. In one telltale sign of which way they’re leaning, demand to borrow 10-year notes in the repurchase-agreement market is so great that rates have gone negative, likely part of a move to short the maturity.The trifecta of more fiscal stimulus ahead, ultra-easy monetary policy and an accelerating vaccination campaign is helping bring a post-pandemic reality into view. There are of course risks to the bearish bond scenario. Most prominently, yields could rise to the point that they spook stocks, and tighten financial conditions generally -- a key metric the Fed is focused on for guiding policy. Even so, Wall Street analysts can’t seem to lift year-end yield forecasts fast enough.“There’s a lot of tinder being put now on this fire for higher yields,” said Margaret Kerins, global head of fixed-income strategy at BMO Capital Markets. “The question is what is the point that higher yields are too high and really put pressure on risk assets and push Powell into action” to try and tamp them down.Share prices have already shown signs of vulnerability to increasing yields, especially tech-heavy stocks. Another area at risk is the housing market -- a bright spot for the economy -- with mortgage rates jumping.The surge in yields and growing confidence in the economic recovery prompted a slew of analysts to recalibrate expectations for 10-year rates this past week. For example, TD Securities and Societe Generale lifted their year-end forecasts to 2% from 1.45% and 1.50%, respectively.Asset managers, for their part, flipped to most net short on 10-year notes since 2016, the latest Commodity Futures Trading Commission data show.Auction PressureIn the days ahead, however, BMO is eyeing 1.75% as the next key mark, a level last seen in January 2020, weeks before the pandemic sent markets into a chaotic frenzy.A fresh dose of long-end supply next week may make short positions even more attractive, especially after record-low demand for last month’s 7-year auction served as a trigger to push 10-year yields above 1.6%. The Treasury will sell a total of $62 billion in 10- and 30-year debt.With expectations for inflation and growth taking flight, traders are signaling that they anticipate the Fed may have to respond more quickly than it’s indicated. Eurodollar futures now reflect a quarter-point hike in the first quarter of 2023, but they’re starting to suggest that it could come in late 2022. Fed officials have projected they’d keep rates near zero until at least the end of 2023.So while the market is leaning toward loftier yields, the interplay between bonds and stocks is bound to be a huge focus going forward.“There’s definitely that momentum, but the question is how well risky assets adjust to the new paradigm,” said Subadra Rajappa, head of U.S. rates strategy at Societe Generale. “We’ll be watching next week, when the dust settles after the payrolls data, how Treasuries react and how risky assets react to the rise in yields.”What to WatchThe economic calendarMarch 8: Wholesale trade sales/inventoriesMarch 9: NFIB small business optimismMarch 10: MBA mortgage applications; CPI; average weekly earnings; monthly budget statementMarch 11: Jobless claims; Langer consumer comfort; JOLTS job openings: household change in net worthMarch 12: PPI; University of Michigan sentimentThe Fed calendar is empty before the March 17 policy decisionThe auction calendar:March 8: 13-, 26-week billsMarch 9: 42-day cash-management bills; 3-year notesMarch 10: 10-year notesMarch 11: 4-, 8-week bills; 30-year bondsFor more articles like this, please visit us at bloomberg.comSubscribe now to stay ahead with the most trusted business news source.©2021 Bloomberg L.P.
22h ago
MarketWatch
After an unseemly stampede, the Nasdaq Composite may be near the end of its correction
Stock-market timers, who as recently as two weeks ago were irrationally exuberant, have reacted to the market’s recent correction by beating a hasty retreat. Consider how quickly the Nasdaq-focused stock-market timers that my firm monitors have jumped on the bearish bandwagon. As recently as Feb. 12, their average recommended exposure level stood at 88.9%, which was higher than 97.9% of all daily readings since 2000.
2d ago
Investopedia
What's the Average 401(k) Balance by Age?
How much money people have put away for retirement varies, naturally, by their age group. See how your savings stack up.
2d ago
InvestorPlace
The Bear Case for IBM Is More Compelling Than the Bull Case
International Business Machines (NYSE:IBM) has had a rough few years, and 2020 was no different. The lack of growth in revenues, earnings, and the stock price reflect its management’s defensive approach towards innovation. However, IBM stock still shows promise. Source: Laborant / Shutterstock.com The company’s new CEO Arvind Krishna could usher in a new era. Krishna aims to make IBM a significant player in the rapidly growing AI and cloud-services sectors. Though it has potential, IBM stock has a lot to prove before it can crawl out of its severe value trap.InvestorPlace - Stock Market News, Stock Advice & Trading Tips Growth has stalled for IBM in the past few years. Its average EBITDA growth over the past five years is at a negative 6.8%. In the past four quarters, revenue growth has been negative. In fact, out of the past 10 quarters, its revenue growth has been negative in nine quarters. Accordingly, IBM stock’s three-year returns are at a negative 20.6% compared to the S&P 500′s returns at 36.7% in the same period. Hence, a lot is at stake with the company’s foray into the AI and cloud businesses. With that being said, let’s look at the bull and bear case for IBM and see which one’s more compelling. The Bull Case Krishna has apparently breathed new life into the company’s operations. He has a vision of seeing IBM as a front-runner in the hybrid cloud and AI businesses. In doing so, he has engineered the acquisition of Red Hat and plans to invest in the company’s declining Managed Infrastructure Services division. 9 Cheap Stocks That Look Like a Bargain IBM is late to the party in the sectors mentioned above. However, Red Hat’s acquisition gives it access to the intellectual capital and hybrid cloud technology to catch-up quickly with its peers. Red Hat’s Open Shift technology allows IBM to scale its hybrid cloud offerings and integrate them with other software. Another attractive aspect of IBM is its dividend profile, which remains undeterred by the effects of the pandemic. It has raised its dividend payouts for 25 years and currently boasts a healthy yield of roughly 5%. With a payout ratio of over 50%, its dividend is well-covered by its earnings. Moreover, the stock is highly undervalued across all significant price metrics. For instance, its forward price to sales ratio is more than 50% lower than the sector median. The Bear Case Now we come to uncomfortable truths regarding IBM, which appears to be more compelling than its bull case. Firstly, the company has failed to generate top-line growth for several years now. It will take time for the new CEO’s vision to come to fruition; hence near-term growth should remain repressed. Moreover, even if things go well in the next few years, it’s tough to say what level of growth it could potentially achieve. With the spin-off of its Managed Infrastructure Services division, IBM will be divesting roughly $19 billion in revenue. This is likely to impact its dividend and total debt. The company has quite a bit of debt, which is divided into core and global financing elements. Its core net debt was at $26.1 billion coupled with its global financing debt worth over $21 billion. Though IBM has done well to generate free cash flows and subsequently pay off its debt, such a massive debt balance is a significant cause for concern. Final Word on IBM Stock IBM is a company in transition. The strategic shift was a long time coming, as the company has struggled to grow for years now. The new CEO’s aggressive push into the AI and cloud businesses are understandable, and could pay dividends down the road. It will be interesting to see how the company can grow its business in the coming future. However, in the near-term, expect more of the same with IBM stock. On the date of publication, Muslim Farooque did not have (either directly or indirectly) any positions in the securities mentioned in this article Muslim Farooque is a keen investor and an optimist at heart. A life-long gamer and tech enthusiast, he has a particular affinity for analyzing technology stocks. Muslim holds a bachelor’s of science degree in applied accounting from Oxford Brookes University. More From InvestorPlace Why Everyone Is Investing in 5G All WRONG It doesn’t matter if you have $500 in savings or $5 million. Do this now. Top Stock Picker Reveals His Next Potential 500% Winner Stock Prodigy Who Found NIO at $2… Says Buy THIS Now The post The Bear Case for IBM Is More Compelling Than the Bull Case appeared first on InvestorPlace.
2d ago
TipRanks
Oppenheimer: 2 Stocks That Could Climb Over 100%
Markets are taking us all for something of a roller coaster ride in recent sessions, alternating gains and drops in precipitous fashion. There’s no telling exactly what comes next, but some of Wall Street’s sharpest minds are on the job. One of those sharp minds is John Stoltzfus, chief investment strategist and managing director at Oppenheimer. Stoltzfus sees us in the preparatory phases of further market gains, and he goes to great lengths to explain his outlook. While he agrees that we have not yet succeeded in putting the COVID-19 pandemic crisis fully behind us, he points out that the data indicate a resilient economy. Stoltzfus starts with the Treasury bond market, which he describes as ‘normalizing.’ Yes, yields are up in recent days from historic lows reached late last summer, but the strategist sees this as evidence that “as the pandemic crisis begins to ebb better times are likely ahead for the US economy.” Stoltzfus goes on to the recent earnings season. Of the corporate earnings reports, Stoltzfus says, “With 97% of companies in the S&P 500 having reported profits are up 5.37% on the back of 2.47% revenue growth—a much stronger result than had been anticipated by consensus analytics at the start of the season.” But solid earnings results are not the only support Stoltzfus offers for his view that better times are ahead of us. Stoltzfus points out the rising price of oil, noting that its year-to-date rise has coincided with the spreading vaccination campaigns and the prospect of economic reopening, and he notes copper. In his words, “The rise in copper prices serves as a sign that expectations are for global growth to accelerate as the world moves out from under the pandemic.” Against this backdrop, one of Stoltzfus’s colleagues at Oppenheimer, 5-star analyst Kevin DeGeeter, has followed up and tapped two stocks that he as primed for big gains in a market rebound, gains on the order of 100% or better. We ran the two through TipRanks database to see what other Wall Street's analysts have to say about them. Evaxion Biotech (EVAX) The first Oppenheimer pick we’re looking at is Evaxion, a biotech company that uses proprietary AI-immunology platforms to develop novel immunotherapies for the treatment of various cancers and infectious diseases. The company currently has two immunotherapy candidates in the clinical trial stage for several cancers, and two other candidates in pre-clinical research. Evaxion went public on the NASDAQ in early February, announcing the pricing of the IPO on February 4 and closing the offering on February 10. The shares were priced at $10 each, the lower end of the range, and the company put 3 million shares on the market, raising gross proceeds of $30 million. The key point to Evaxion, as far as investors are concerned, are the two candidates in Phase IIa clinical trials. The candidates, EVX-01 and EVX-02, are designed to be patient-specific treatments for non-small-cell lung cancer, bladder cancer, and various types of melanoma. Results for both candidates’ studies are expected in the first half of 2021. DeGeeter initiated coverage on this stock in early March, basing his optimism on “1) Artificial Intelligence-driven immunology platform generating a broad portfolio; 2) personalized cancer vaccines, EVX-01 and EVX-02, with two important Phase I/IIa updates in 2Q21; 3) capital-efficient business mode…” At the bottom line, DeGeeter writes, “We view EVAX as an AI platform story with multiple differentiated programs either in early-stage human studies or nearing clinical development. Our near term focus is on the oncology platform…” In line with his upbeat outlook, DeGeeter rates EVAX an Outperform (i.e. Buy), and his $18 price target implies a robust upside of 157% for the coming year. (To watch DeGeeter’s track record, click here) DeGeeter’s review is one of two that have been published on EVAX, but both are Buys, making the consensus here a Moderate Buy. The stock is selling for $7, and the average price target is $18, the same as DeGeeter’s. (See EVAX stock analysis on TipRanks) Sensei Biotherapeutics (SNSE) For the second stock on our short list from Oppenheimer, we’re staying in the biotech industry. Like Evaxion above, Sensei Biotherapeutics is an immunotherapy research company with a focus on cancer treatments; what makes Sensei different is its platform, using a bacteriophage to deliver the therapeutic agent and trigger an immune response in the patient. In another similarity to Evaxion, Sensei held its IPO in February. The company put 7 million shares of common stock on the market, at a price of $19 per share, and closed its first day’s trading at $18.90. The IPO grossed a total of $152.6 million, and the company now boasts a market cap of $418 million. That company's leading candidate, SNS-301, is an experimental cancer vaccine that targets the overexpression of aspartyl beta hydroxylase (ASPH) in squamous cell carcinomas of the head and neck. The product is in Phase I/II development, and preliminary data demonstrated long duration of response, including 30+ weeks disease stability in 2 patients. Further data is expected in the second half of this year. In his note initiating coverage on Sensei Biotherapeutics, DeGeeter takes an optimistic view. “We view SNSE's ImmunoPhage immuno-oncology platform as offering important differentiation based on 1) potential to easily combine low-cost off-the-shelf and personalized neoepitopes in a single product, 2) self-adjuvant profile of ImmunoPhage, and 3) rapid turnaround time of ~four weeks for personalized neoepitope production. Our positive outlook is based on potential for Phase I/II study of SNS-301 ASPH ImmunoPhage to demonstrate clinically meaningful benefit in first-line treatment and neoadjuvant head and neck cancer settings based on improved durability of response,” DeGeeter commented. To this end, DeGeeter puts an Outperform (i.e. Buy) rating on SNSE shares, along with a $36 price target that indicates potential for ~141% upside over the next 12 months. (To watch DeGeeter’s track record, click here) Sensei has only been a public company for a few weeks, but in that time it has attracted 4 analyst reviews – all are Buys, making the analyst consensus view a unanimous Strong Buy. Shares are priced at $14.95 and have an average price target of $29.50, which implies a one-year upside of ~97%. (See SNSE stock analysis on TipRanks) To find good ideas for stocks trading at attractive valuations, visit TipRanks’ Best Stocks to Buy, a newly launched tool that unites all of TipRanks’ equity insights. Disclaimer: The opinions expressed in this article are solely those of the featured analysts. The content is intended to be used for informational purposes only. It is very important to do your own analysis before making any investment.
2d ago

Symbol	Last Price	Change	% Change
CBRE CBRE Group, Inc.	77.28	+0.65	+0.85%
CSNA3.SA Companhia Siderúrgica Nacional	37.00	+1.79	+5.08%
PAGS PagSeguro Digital Ltd.	53.10	+0.47	+0.89%
PSX Phillips 66	87.43	+3.02	+3.58%
SID Companhia Siderúrgica Nacional	6.46	+0.31	+5.04%

S&P 500

Dow 30

Nasdaq

Russell 2000

Crude Oil

Gold

Silver

EUR/USD

10-Yr Bond

GBP/USD

USD/JPY

BTC-USD

CMC Crypto 200

FTSE 100

Nikkei 225

Ken Heebner's Firm Exits Zebra Technologies, Phillips 66

Recommended Stories

Joe Biden says this is when the next stimulus checks will go out

To get the next stimulus check, you may want to hustle with your taxes

Cathie Wood’s New Tesla Target Price Is Coming Soon. Here’s Where It Might Land.

Getting A Third Covid-19 Stimulus Check Just Got Tougher — But You Might Still Influence How Big Yours Is

Joe Biden's stimulus check changes: Do you still qualify for $1,400?

JPMorgan Bets on These 3 Stocks; Sees Over 50% Upside Potential

How stimulus checks can give you a $14,000 windfall this year

Churchill Capital IV Will Likely Create Shareholder Value

Carnival Is Climbing Too High Too Fast

Roblox goes public, inflation data: What to know in the week ahead

Why Cathie Wood Is Bullish On DraftKings

Biggest Players in the Short-Selling Game Are Getting a Pass

Elon Musk Loses $27 Billion as Historic Wealth Gains Unravel

Chamath Palihapitiya Shares Lessons Learned After Tough Week For SPACs

Suze Orman: Something's ‘radically wrong’ if you’re getting a tax refund

Bond Traders Go All-In on U.S. Treasury Market’s Big Short Bet

After an unseemly stampede, the Nasdaq Composite may be near the end of its correction

What's the Average 401(k) Balance by Age?

The Bear Case for IBM Is More Compelling Than the Bull Case

Oppenheimer: 2 Stocks That Could Climb Over 100%